PharmNovo starts clinical phase I studies of a drug candidate for neuropathic pain
PharmNovo AB, a Swedish pharmaceutical company developing drugs for neuropathic pain, so-called nerve pain, today announces that phase I studies of the drug candidate PN6047 have been initiated.The drug candidate PN6047 from PharmNovo is an entirely new drug. The substance is a selective delta opioid, a so-called DORA (delta opioid receptor agonist), which, in animal models, effectively relieves nerve pain. It does so without causing the unwanted side effects of conventional opioid drugs on the market today.
During the summer, the application to start clinical studies of PN6047 was